Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alfa-2a versus hydroxyurea in high-risk polycythemia vera and essential thrombocythemia
2010-019501-41Phase 3Active
- Sponsor
- Consorzio Mario Negri Sud
- Start
- Jan 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in polycythemia vera (PV) and thrombocythemia comparing Pegasys with hydroxyurea (2 arms). Primary endpoints: Complete hematologic response in essential thrombocythemia and Complete hematologic response in polycythemia vera. Started Jan 2012; status: active.
02
Drugs
interferon alfahydroxyurea
03
Conditions
polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on 2010-019501-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019501-41.